Author + information
- Received December 19, 1984
- Revision received March 19, 1985
- Accepted April 2, 1985
- Published online August 1, 1985.
- J. Kevin Drury, MD, FACCa,
- Shigeru Yamazaki, MD,
- Michael C. Fishbein, MD, FACC,
- Samuel Meerbaum, PhD, FACC and
- Eliot Corday, MD, FACC
- ↵aAddress for reprints: J. Kevin Drury, MD, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Halper 325, Los Angeles, California 90048.
The safety and efficacy of a new clinical synchronized diastolic retroperfusion mechanical pump and autoinflatable balloon catheter was studied in 10 dogs during and after 6 hours of left anterior descending coronary artery occlusion. Eight other dogs served as the untreated control group. Infarct size measured by triphenyltetrazolium chloride, and expressed as a percent of area at risk, was significantly reduced by retroperfusion treatment (19 ± 18 versus 58 ± 36, p < 0.01). Morphologic examination of the coronary sinus and cardiac veins did not demonstrate evidence of damage from synchronized retroperfusion. There was also no evidence of excess myocardial edema in either the jeopardized ischemic or normally perfused zones. There was no evidence of significant red cell hemolysis or platelet destruction from the treatment. Thus, it appears that synchronized diastolic retroperfusion is a safe and effective treatment of acute myocardial ischemia in experimental animals and warrants clinical testing.
This study was presented in part at the 57th Annual Scientific Sessions of the American Heart Association, Inc., Miami, Florida, November 1984. It was supported in part by Grants HL 1756108 and HL 14644-09 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; Canadian Heart Foundation, Ottawa, Ontario, Canada; The Medallion Group of Cedars-Sinai Medical Center and the W. M. Keck Foundation, Los Angeles, California.
- Received December 19, 1984.
- Revision received March 19, 1985.
- Accepted April 2, 1985.
- American College of Cardiology Foundation